-
Danazol C3644 for Reliable Cell Assays
2026-08-26
Learn how Danazol (SKU C3644) can improve the interpretability of viability, proliferation, and endocrine-modeling assays through controlled solubilization, matched vehicle controls, and mechanism-aware data analysis. The article connects product specifications with recent Danazol animal-model evidence and practical vendor-selection criteria.
-
Ferroptosis, Apoptosis, and BH3-Mimetic Modulation
2026-08-26
The 2025 Cell Death & Differentiation study shows that ferroptosis and apoptosis can intersect rather than function as fully independent death programs. Its most important practical finding is that BH3 mimetics may either intensify and redirect ferroptotic death toward apoptosis or unexpectedly suppress death through intrinsic antioxidant activity, depending on cellular context and exposure conditions.
-
Niclosamide: From STAT3 Mechanism to Translation
2026-08-25
Niclosamide offers translational researchers a mechanism-led way to interrogate STAT3 biology, connect Tyr-705 phosphorylation with cell fate, and design more informative preclinical workflows. This article places its cancer research applications alongside lessons from a recent molluscicidal study, while clearly separating evidence, interpretation, and future opportunity.
-
LY2109761: TGF-β Receptor I/II Inhibitor
2026-08-25
LY2109761 enables pathway-focused studies of TGF-β-driven signaling, invasion, fibrosis, and radiation response without relying on phenotype alone. This workflow connects early Smad2/3 phosphorylation measurements with migration, invasion, stemness, and preclinical treatment readouts.
-
Concanamycin A: Reliable V-ATPase Assays
2026-08-24
Learn how Concanamycin A (SKU A8633) can improve mechanistic interpretation and workflow consistency in cell viability, apoptosis, trafficking, and invasion studies. This scenario-based guide connects V-ATPase inhibition with practical dosing, storage, compatibility, and data-quality decisions.
-
Rapamycin and Autophagic Flux in Macrophages
2026-08-24
Rapamycin (Sirolimus) is best known as a potent mTOR-pathway inhibitor, but it can also serve as a mechanistic probe for separating autophagy initiation from autophagic flux. This article translates macrophage–Staphylococcus aureus findings into a careful experimental framework for immunology and infection research.
-
4-Hydroxytamoxifen Workflow Guide
2026-08-23
This guide explains how to prepare, store, and quality-check 4-Hydroxytamoxifen (SKU B6167) for DMSO-based estrogen receptor modulation workflows. It is suited to controlled cell and cardiac studies but should not be selected for protocols requiring direct water or ethanol solubility, and no paper-matched dose or exposure schedule is assigned here.
-
EV-Transferred ACLY Drives TAMs in HCC
2026-08-22
A recent Advanced Science study identifies extracellular vesicle-transferred ATP-citrate lyase as a metabolic signal that redirects monocytes toward immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its combination of native EV analysis, CD81-decorated liposomal mimics, and ACLY-targeted intervention links lipid synthesis to immune-checkpoint stability and improved anti-PD-1/PD-L1 responses in experimental models.
-
10058-F4: Reframing c-Myc Translational Research
2026-08-22
A thought-leadership guide to using 10058-F4 as a mechanistic probe in c-Myc biology, acute myeloid leukemia research, apoptosis assays, prostate cancer xenograft studies, and emerging telomerase-related questions.
-
EHEC Prevents Danazol-Induced Precocious Puberty
2026-08-21
Kim and colleagues evaluated an Eclipta prostrata–Hordeum vulgare extract complex in rat models of precocious puberty induced by Danazol or a high-fat diet. The extract delayed vaginal opening, reduced ovarian maturation, and attenuated hypothalamic GnRH mRNA elevation without changing body weight, supporting modulation of the hypothalamic–pituitary–gonadal axis as the study’s central finding.
-
Toremifene Workflows for Prostate Cancer Research
2026-08-20
Toremifene provides a practical way to perturb estrogen receptor activity while linking cell-growth, migration, and calcium-signaling readouts in hormone-responsive cancer models. This workflow-focused guide shows how to use its reported in vitro potency to build reproducible assays and interpret exploratory connections to the STIM1-driven metastatic phenotype.
-
EPI-001: Reliable AR Assay Design
2026-08-20
This scenario-based guide explains how EPI-001 (SKU B6041), an androgen receptor N-terminal domain inhibitor, can support reproducible viability, proliferation, and cytotoxicity workflows in AR-driven cancer models. It connects formulation control, assay design, and interpretation across prostate cancer and carefully bounded TNBC research.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows
2026-08-19
Build more interpretable cytoskeletal, organoid, stem-cell, and invasion assays with Y-27632 dihydrochloride, a selective ROCK1/2 inhibitor. This guide connects mechanism to practical dosing, organoid recovery workflows, quantitative readouts, and troubleshooting while distinguishing established product properties from proposed assay extensions.
-
Rucaparib and the Splicing–DNA Repair Axis
2026-08-19
Rucaparib (AG-014699, PF-01367338) offers translational researchers a way to interrogate PARP1-dependent DNA repair, radiosensitization, and emerging spliceosome-linked vulnerabilities. New hepatocellular carcinoma findings suggest that SmD2 acetylation may help define PARP inhibitor sensitivity beyond canonical BRCA1/2 deficiency.
-
WEHI-539: The Logic of BCL-XL Dependency
2026-08-18
A translational framework for using WEHI-539 to distinguish BCL-XL dependency from generalized apoptotic sensitivity, validate mitochondrial death mechanisms, and design more informative cancer and cancer stem cell studies.